Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA ‘Consumer Centric’ Model Boosts Product Lines, Shapes R&D

This article was originally published in The Tan Sheet

Executive Summary

Merck KGaA launches additional OTC products from brands associated with doctors or behind-the-counter sales or that currently are Rx to yield double-digit organic growth. The German firm is soliciting consumer feedback to shape its R&D and improve its understanding of factors driving the OTC market.

You may also be interested in...



Merck KGaA Consumer Engages Social Media To Grow In Europe, Latin America

The German firm will expand its digital engagement strategy, having achieving strong followings with the strategy for three brands in Europe and/or Latin America. Initiative reflects company's larger "consumerization" strategy.

Merck KGaA Consumer Engages Social Media To Grow In Europe, Latin America

The German firm will expand its digital engagement strategy, having achieving strong followings with the strategy for three brands in Europe and/or Latin America. Initiative reflects company's larger "consumerization" strategy.

Climb In Consumer Self-Care, Slide In Rx Margin Boost Front-Of-Store Pharmacy Sales

OTC drug and supplement marketers could benefit from stronger outreach to independent pharmacists, via product education and patient sales collateral, pharmacists say in a Healthcare Distribution Management Association survey.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS107739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel